Trial Condition(s):

Venous thrombosis

Belgian real life non-interventional study (NIS) in patients treated with Xarelto following an acute deep vein thrombosis (DVT) (BOX-DVT)

Bayer Identifier:

16852

ClinicalTrials.gov Identifier:

NCT01855100

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated with Xarelto, in accordance with the terms of the European marketing authorization and the Belgian reimbursement criteria.

Inclusion Criteria
- Adult patients with a diagnosis of deep vein thrombosis (DVT) within the past 9 months, enabling at least 3 months of therapy
Exclusion Criteria
- Patients who do not fulfil the Belgian reimbursement criteria of deep vein thrombosis (DVT)

Trial Summary

Enrollment Goal
131
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Belgium

Status
Completed
 

Trial Design